Kévin Chemello

647 total citations
22 papers, 423 citations indexed

About

Kévin Chemello is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Kévin Chemello has authored 22 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 8 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Cancer Research. Recurrent topics in Kévin Chemello's work include Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Cancer, Lipids, and Metabolism (8 papers). Kévin Chemello is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Cancer, Lipids, and Metabolism (8 papers). Kévin Chemello collaborates with scholars based in France, Réunion and South Africa. Kévin Chemello's co-authors include Gilles Lambert, Valentin Blanchard, Brice Nativel, Stéphane Ramin‐Mangata, Mikaël Croyal, Dirk Blom, Dick C. Chan, Steeve Bourane, Bertrand Cariou and Matthieu Pichelin and has published in prestigious journals such as International Journal of Molecular Sciences, Arteriosclerosis Thrombosis and Vascular Biology and Journal of Lipid Research.

In The Last Decade

Kévin Chemello

21 papers receiving 423 citations

Peers

Kévin Chemello

SURGE

EDM

CCM

Marion Cousins Canada

Raffaele Fresa Italy

Bei Wang China

Laurent Kassalow United States

Mark A. Spahr United States

Mitsuaki Ishihara Japan

Vincenza Valenti Italy

Thilina Dewpura Canada

Sanae Kourimate France

Hendrik du Toit Theron United States

Marion Cousins Canada

Kévin Chemello

497 ×1.6

SURGE

126 ×1.0

EDM

116 ×1.0

68 ×0.8

CCM

96 ×1.2

Citations per year, relative to Kévin Chemello Kévin Chemello (= 1×) peers Marion Cousins

Countries citing papers authored by Kévin Chemello

Since Specialization

Citations

This map shows the geographic impact of Kévin Chemello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kévin Chemello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kévin Chemello more than expected).

Fields of papers citing papers by Kévin Chemello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kévin Chemello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kévin Chemello. The network helps show where Kévin Chemello may publish in the future.

Co-authorship network of co-authors of Kévin Chemello

This figure shows the co-authorship network connecting the top 25 collaborators of Kévin Chemello. A scholar is included among the top collaborators of Kévin Chemello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kévin Chemello. Kévin Chemello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Veeren, Bryan, Cynthia Planesse, Matthieu Bringart, et al.. (2025). PCSK9 deficiency promotes the development of peripheral neuropathy. JCI Insight. 10(12). 2 indexed citations

Chemello, Kévin, et al.. (2025). Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL Trial. Journal of the American Heart Association. 14(9). e036630–e036630.

Chemello, Kévin, Antonio Gallo, Alexis F. Guédon, et al.. (2023). Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors. JACC Advances. 2(7). 100557–100557. 5 indexed citations

Chemello, Kévin, et al.. (2023). PCSK9 and the nervous system: a no-brainer?. Journal of Lipid Research. 64(9). 100426–100426. 14 indexed citations

Chemello, Kévin, Bryan Veeren, Brice Lortat‐Jacob, et al.. (2023). Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study. International Journal of Molecular Sciences. 24(5). 4605–4605. 7 indexed citations

Chemello, Kévin, et al.. (2022). Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis. 349. 82–91. 35 indexed citations

Croyal, Mikaël, Matthieu Wargny, Kévin Chemello, et al.. (2022). Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular Diabetology. 21(1). 21–21. 16 indexed citations

Suchowerska, Alexandra K., Geurt Stokman, James T. Palmer, et al.. (2022). A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo. Journal of Lipid Research. 63(11). 100293–100293. 15 indexed citations

Chemello, Kévin, Dirk Blom, A. David Marais, Gilles Lambert, & Valentin Blanchard. (2022). Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. Current Atherosclerosis Reports. 24(6). 399–405. 1 indexed citations

10.

Chemello, Kévin, Javier García‐Nafría, Antonio Gallo, et al.. (2021). Lipoprotein metabolism in familial hypercholesterolemia. Journal of Lipid Research. 62. 100062–100062. 29 indexed citations

11.

Blanchard, Valentin, Kévin Chemello, Tim Hollstein, et al.. (2021). The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Cardiovascular Research. 118(9). 2103–2111. 20 indexed citations

12.

Uribe, Kepa B., Kévin Chemello, Asier Larrea‐Sebal, et al.. (2021). A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. International Journal of Molecular Sciences. 22(24). 13602–13602. 9 indexed citations

13.

Evison, Benny J., James T. Palmer, Gilles Lambert, et al.. (2020). A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Bioorganic & Medicinal Chemistry. 28(6). 115344–115344. 36 indexed citations

14.

Chemello, Kévin, Sandra Beeské, Thi Thu Trang Tran, et al.. (2020). Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC Basic to Translational Science. 5(6). 549–557. 19 indexed citations

15.

Blanchard, Valentin, Kévin Chemello, Stéphanie Billon‐Crossouard, et al.. (2020). A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. Journal of Lipid Research. 61(7). 1128–1139. 28 indexed citations

16.

Huijgen, Roeland, Dirk Blom, Merel L. Hartgers, et al.. (2020). Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis Thrombosis and Vascular Biology. 41(2). 934–943. 6 indexed citations

17.

Croyal, Mikaël, Jean-Christophe Le Bail, Elise F. Villard, et al.. (2018). PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. Clinical Science. 132(10). 1075–1083. 35 indexed citations

18.

Blanchard, Valentin, et al.. (2018). PCSK9: from biology to clinical applications. Pathology. 51(2). 177–183. 37 indexed citations

19.

Blanchard, Valentin, Stéphane Ramin‐Mangata, Stéphanie Billon‐Crossouard, et al.. (2018). Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. Journal of Lipid Research. 59(5). 892–900. 28 indexed citations

20.

Thedrez, Aurélie, Dirk Blom, Stéphane Ramin‐Mangata, et al.. (2017). Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis Thrombosis and Vascular Biology. 38(3). 592–598. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact